This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
789TiPHALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA). (23rd October 2018)
Record Type:
Journal Article
Title:
789TiPHALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA). (23rd October 2018)
Main Title:
789TiPHALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA)